 |
| SK플라즈마 안동 공장 전경 (사진=SK플라즈마) |
[Alpha Biz=(Chicago) Reporter Paul Lee] SK Plasma will invest 300 billion won near Jakarta, Indonesia, to set up a production plant for overseas blood fraction products. It is scheduled to be completed in 2025 and is expected to produce 1 million ℓ annually, 1.6 times more than the current Andong plant.
According to SK Discovery on the 7th, SK Plasma, a blood product business subsidiary, is recently in the process of signing a contract for a local production facility in Indonesia. It has established a joint venture with Indonesian pharmaceutical company Inpion to secure approval for production facilities by local regulatory authorities.
This factory produces medicine using plasma that separates in human blood.
Meanwhile, Indonesia currently does not have its own production facilities for blood fractions, so it relies on imports.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
